Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review Authors: Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Carla Mazzone, Maria Ilaria Del Principe Published: 2026 ABSTRACT AbstractContext/Objective. Myelodysplastic Syndromes/Neoplasms (MDS) are a heterogeneous group of blood cancers characterized by a broad spectrum of symptoms and varying impacts on quality of life (QoL). Although the integration of early PC care has long been recognized as an essential part of comprehensive management for patients with solid tumors, experience in the context of MDS is still limited. However, symptom control, QoL, advanced care planning goals, the reduction of aggressive therapies, intensive care use, including intubation before death, and resource use in the end-of-life (EOL) phase are critical issues that are enhanced through early PC in MDS management. Additionally, integrating standard hematological measures with early PC leads to fewer visits and hospital admissions near the EOL, particularly during the last 30 days. Moreover, patients with early PC die at home or in hospice care at a rate nearly in line with their preferences. Therefore, routine early PC is a critical issue for patients with MDS, regardless of disease risk, as it improves patient outcomes, enhances communication, refines resource use, and reduces unnecessary aggressive procedures.Keywords: Early palliative care, Care at the end of life, Hospice care, Myelodysplastic syndromes, Quality of life, Symptoms management, Transfusion support Introduction: brief general overview of MDS Managing myelodysplastic syndromes (MDS) is still a major challenge in modern hematology [1]. This diverse group of blood-related disorders includes heterogeneous myeloid neoplasms characterized by one or more peripheral cytopenias due to ineffective hematopoiesis, with a variable risk of progressing to acute myeloid leukemia (AML) [1–4]. MDS is a disease that typically affects older adults, who may often suffer from concomitant comorbid conditions or are at high risk of developing them [5, 6]. The pathogenesis of MDS is multifactorial, arising from a complex interplay between intrinsic genetic abnormalities in hematopoietic stem cells and their malignant environment [3, 5]. Recent advances in the pathophysiological understanding of MDS and in genomic techniques have enabled the detection of molecular features, leading to novel diagnostic and prognostic capabilities and new targeted therapeutic approaches [1, 3, 7–11]. In line with these advances, new classification systems have been developed (Table 1) [12, 13]. Notably, genomic advances in research on the “transition” period from “MDS syndrome” to “specific pathologies” amenable to targeted therapy highlight the growing importance of molecular data over blast count in such a setting [8, 9, 11]. Table 1Comparison of the 5th edition WHO and the 2022 ICC classifications* of MDSBM blasts5th edition WHO^ICC 2022Notations and comments: MDS are termed “myelodysplastic neoplasms.”< 5%MDS low blastsMDS-SLDIncluding both MDS-SLD (dysplasia > 10% for a single lineage) and MDS-MLD (dysplasia > 10% for more than one lineage).MDS-RSMDS-RS°also in the absence of SF3B1mutationMDS isolated del (5q)MDS isolated del (5q)No changesBiallelic TP53 inactivation5%−9%MDS IB1MDS EB^ “increased” instead of “excess” of blasts> 5%MDS-f^BMF grade 2 or 3 and BM blasts > 5%10%−19%MDS IB2°MDS/AML20%AMLAMLBoth classifications adopt this blast cut-off to distinguish MDS from AML.*Adapted from references 12 and 13.BM bone marrow, MDS myelodysplastic syndromes/neoplasms, SLD single lineage dysplasia, MLD multilineage dysplasia, IB1 increased blasts-1, IB2 increased blasts-2, EB excess of blasts, f fibrosis, BMF bone marrow fibrosis, AML acute myeloid leukemia Comparison of the 5th edition WHO and the 2022 ICC classifications* of MDS BM bone marrow, MDS myelodysplastic syndromes/neoplasms, SLD single lineage dysplasia, MLD multilineage dysplasia, IB1 increased blasts-1, IB2 increased blasts-2, EB excess of blasts, f fibrosis, BMF bone marrow fibrosis, AML acute myeloid leukemia Early palliative care (PC) in the context of the symptom burden of MDS From a clinical point of view, MDS are diseases that are heterogeneous and cause health deterioration or a life-threatening clinical course and severe medical complications. In this regard, affected patients face disease-related concerns, particularly physical and mental challenges, as well as uncertainty about AML evolution [4, 5, 14]. Significantly, MDS presents a complex shared experience for affected individuals and their caregivers, who are engaged in affectionate and empathetic involvement with patients’ suffering, regularly visit hospitals for treatment, and experience a significant reduction in QoL [14–18]. In this regard, the early integration of PC interventions can enable a multidisciplinary approach to enhance QoL for patients with life-threatening or chronic troublesome conditions as well as to support their caregivers [19–23]. In this regard, early PC refers to a specific period after diagnosis, while prompt PC is tailored to each patient [24]. Moreover, early PC serves as a bridge between the disease’s clinical presentation and patients’ personal values by conducting prompt conversations about prognosis and goals of care, significantly reducing the likelihood of a high-yield, unnecessary hospitalization in the final month of life [25–30]. Furthermore, early PC can foster an empathetic environment in which patients and caregivers feel comfortable sharing their concerns and needs with the hematological team, especially regarding disease awareness, informed discussions of treatment options, and the practical and financial strain involved in daily care for their loved ones [22, 28–33]. Additionally, early PC not only reduces patients’ symptoms but also alters their overall disease course, enabling them to tolerate therapies better and adhere more closely to regimens of causal and supportive measures [30, 34]. Table 2 highlights the main aspects of symptom burden in MDS that can receive help from early PC interventions [14–16, 30–37]. Table 2Key aspects of symptom burden in MDS needing early palliative careSymptom Domain [references]Specific ManifestationsUnderlying Pathogenesis/ChallengePalliative TargetPhysical [5, 17, 30–32]Fatigue, Dyspnea, Infections, Pain, Bleeding.Anemia (Multifactorial), Cytopenias, Disease- or Treatment-related adverse effects.Symptom management, transfusion schedule optimization, and pain control.Logistical/Practical [5, 14, 16, 17]Transfusion dependence (Tethering), Limitation of movements, Loss of familiar roles.Required frequent medical center visits, physical symptom burden, and negative self-image.Counseling, resource navigation, and optimizing home care logistics.Psychosocial[16, 17, 35–37]Anxiety, Depression, Fear of Death, Uncertainty, Decreased sexual interest.Fear of disease course/complications, mood disorders, and prognosis uncertainty.Psychological screening, targeted psychotherapy, and spiritual support.Systemic[14–17, 33]Financial Toxicity, Family Burden, Decreased Performance Status.High cost of care, extensive caregiver needs, and disease-related functional decline.Social work intervention, financial resource planning, family meetings, and rehabilitation assessment. Key aspects of symptom burden in MDS needing early palliative care Psychosocial [16, 17, 35–37] Systemic [14–17, 33] The path of early PC in MDS Historically, hematologic patients faced a significant “palliative care gap”, receiving fewer consultations and more EOL interventions than others affected by solid tumors [38–41]. However, greater awareness has led major oncological groups to recommend early PC also for all hematological malignancies, regardless of prognosis or the intensity of antineoplastic interventions [42–47]. Indeed, since 2011, the Center to Advance Palliative Care has affirmed that this model of holistic clinical management is right at any stage of an illness [42]. In addition, in the same year and as more recently reaffirmed, ASCO has recommended early consideration of combined standard oncology and PC for any patient with advanced malignancies experiencing a high symptom burden [43, 44]. Notably, the latest 2024 ASCO Palliative Care Guidelines update is truly a historical step for hematology [44]. Furthermore, the NCCN guidelines for PC in oncology highlighted its importance in the management of malignant diseases, particularly for enhancing patient QoL, and recommended initiating PC treatment early during care, alongside other antineoplastic treatments, while also emphasizing the need to encourage adaptive coping skills in patients and caregivers [45]. Again, the ESMO guidelines on MDS highlighted tailored management that considers the patient’s age, comorbidities, and genetic findings, as well as early PC to control symptoms and improve QoL [46]. Of note, more recently, NCCN guidelines for MDS prioritize a multidisciplinary approach, incorporating early PC alongside disease-modifying therapies to manage symptoms such as anemia, fatigue, and pain, and to improve QoL, supportive care, and patient-centered decision-making, which should be tailored to risk stratification [47]. Notably, in line with ASCO guidelines, PC should include two layers: primary and specialty PC [44, 48]. In this regard, all medical providers involved in the care of cancer patients should provide primary PC, including basic symptom screening, distress management, and advanced care planning [48]. Specialty PC, provided by a team of physicians, nurses, psychologists, social workers, and chaplains, should be initiated as soon as possible, including for patients with hematologic malignancies who need palliation for a burdensome symptom burden or are at higher disease risk [2, 47–50]. Primary PC, provided directly by hematologists, is an essential focus of clinical management for most patients with MDS over a substantial course of disease. In this view, it should also be considered that the shortage of specialist PC clinicians makes it unfeasible to provide PC consultations for all patients diagnosed with MDS [47, 48]. Therefore, it is necessary to develop a risk-stratified approach to determine which specialty PC to deliver to patients in need of palliation at the appropriate time, according to current prognostic tools [10, 18, 24, 44, 51]. In contrast, PC in hematological malignancies, such as MDS, has always been synonymous with EOL care [17, 39–41, 52–55]. This reality means that specialty PC services may have been consulted only very late in the patient’s disease course, resulting in aggressive disease-modifying therapy in the final phase of the EOL [52–55]. Research indicates that MDS has a substantial impact on patients’ QoL, yet information on PC within the context of MDS remains limited [1, 16, 40]. This narrative review assesses the current state and future outlook of PC in treating MDS, emphasizing its advantages, limitations, and the challenges posed by the disease’s complexity [1, 56]. Methods This article is a narrative review and not a systematic one. Therefore, it is usually subjective and intended to collect as much information as possible in this rapidly advancing field of PC therapy in MDS. The papers included in the review article, following an iterative criterion, were identified in PubMed through April 2026 using basic keywords, including early PC, EOL care, hematological malignancies, PC, quality of life, acute myeloid leukemia, and symptom control. The research was iterative, and keywords were repeatedly changed by returning to the database to add new terminologies found in the literature. In addition, the selected articles included peer-reviewed papers, rigorous randomized controlled trials, reviews, editorials, and important non-randomized studies. They were chosen by consensus among all authors for their clinical significance, based on the authors’ expert opinion and judgment. Prognostication models of MDS as tools for referral timing to PC The clinical management of MDS is one of the complex challenges in modern hematology, given its heterogeneous biological and clinical features and unpredictable outcomes, ranging from indolent disease that can last decades to aggressive disease course with overall survival (OS) [1, 3, 56]. Therefore, right prognostication and risk stratification, based on key molecular, biological, and clinical disease features, are essential to a patient-centric approach in such a setting [10, 51, 57–59]. In this regard, it’s essential to differentiate between patients who need a symptom-tailored approach and those who require disease-modifying therapies, as well as to find the proper timing of PC integration [30, 60]. The IPSS-R score uses five weighted variables, including blast percentage in bone marrow, karyotype, hemoglobin level, platelet count, and absolute neutrophil count, to assess the predicted OS and the risk of progression to AML [51]. These categories quickly distinguish declining MDS cases from more chronic ones. However, in the era of precision medicine, the transition from using clinical-cytogenetic characteristics to assess the IPSS-R score to new scoring systems, such as the Molecular IPSS (IPSS-M), has been associated with increased predictive power for OS and leukemic transformation [10]. Indeed, the IPSS-M, which involves a 31-gene mutation panel, when combined with clinical factors, improves the prognostic accuracy [10]. The introduction of IPSS-M can lead to changes in practice by reclassifying a substantial proportion of patients with MDS, upstaging their disease risk. In this concept, certain high-impact genomic markers (e.g., TP53 multi-hit or complex karyotypes) can serve as triggers for initiating prompt and intensive clinical management, early PC, serious-illness conversations, and advanced care planning procedures for EOL care [7–10, 28, 61]. Therefore, the IPSS-R allows the selection of the appropriate timing for initiating PC based on clinical features [51]. At the same time, IPSS-M allows for additional triggers based on molecular factors [8, 10, 62]. Therefore, these diverse triggers can allow for distinguishing needs-based vs. time-based PC Referral (Tables 3 and 4). However, in patients with MDS, IPSS-M still faces challenges due to limited access to comprehensive molecular profiling in routine clinical practice [58, 59]. As a result, the IPSS-R is still the most widely used prognostic tool across various MDS settings [59]. Thus far, the following sections address the clinical management and criteria for early PC referral following a tailored risk approach to patients belonging to the three risk categories of MDS, such as lower, intermediate, and higher risk, respectively, as defined by IPSS-R (Table 3). Table 3Integration of Palliative Care Timing Based on IPSS-R Risk Stratification in MDSIPSS-R Risk categoryRisk scoreMedian OS(years)PC integration strategyMandatory referral triggerReferencesVeryLow-Risk< 1.58.8The hematology team mainly handles symptom screening and supportive care and provides educational resources.Development of persistent TD, new significant disease-related comorbidities, or functional decline. Proactive palliative care consultations are advised when there is a high symptom burden or distress, symptomatic cytopenias, or a decrease in QoL.[18, 24, 47, 51, 63]Low-Risk> 1.5–35.3[18, 24, 47, 51, 63]Intermediate-Risk> 3–4.5About 3.0 (highly variable)Proactive, integrated specialist PC consultation conducted concurrently with the initial DMT start.Early PC is strongly recommended for systematic integration, ideally within 8 weeks of diagnosis or disease progression/clear failure of disease-modifying therapy.[9, 18, 24, 51, 64]High-Risk> 4.5–61.6Administer active treatment along with immediate PC consultation, including mandatory GOC and ACP.Mandate the immediate and systematic integration of early PC alongside disease-modifying therapy (e.g., HMA), ideally starting at diagnosis, as with AML.[18, 24, 30, 51, 65, 66]Very High-Risk> 60.8Immediate, systematic integration of PC is required for GOC and ACP planning, as well as for intensive symptom management in EOL care.[18, 24, 30, 51, 65, 66]IPSS-R revised international prognostic system, OS overall survival, PC palliative care, TD transfusion dependence, QoL quality of life, MTD multidisciplinary team, HMA hypomethylating agents, AML acute myeloid leukemia, GOC goals of care, ACP advanced care planning, EOL end of life care Integration of Palliative Care Timing Based on IPSS-R Risk Stratification in MDS Very Low-Risk IPSS-R revised international prognostic system, OS overall survival, PC palliative care, TD transfusion dependence, QoL quality of life, MTD multidisciplinary team, HMA hypomethylating agents, AML acute myeloid leukemia, GOC goals of care, ACP advanced care planning, EOL end of life care Table 4Needs-based vs. time-based PC referral triggersTrigger categoryCriteria examples for specialist PC referralReferencesPhysical NeedsPain, dyspnea, or fatigue.[18, 44, 47, 67]Psychosocial NeedsModerate-to-severe anxiety/depression; request for hastened death.[35, 36, 44, 54]Decision-MakingDisagreement over goals of care; request for “futile” therapy Potenza.[21, 22, 53–55]Biological TriggerIPSS-M “Very High” risk; TP53 multihit mutation IPSS-M[8, 10, 18, 62]Clinical EventsICU admission > days; Multiple organ failure; Recurrent infections.[18, 30, 68]Disease TrajectoryFailure of second-line HMA therapy; eligibility for Phase I trials.[18, 30, 44, 47, 54, 55]PC palliative care, IPSS-M molecular international prognostic scoring system, TP53 tumor protein p53, ICU intensive care unit, HMA hypomethylating agents Needs-based vs. time-based PC referral triggers PC palliative care, IPSS-M molecular international prognostic scoring system, TP53 tumor protein p53, ICU intensive care unit, HMA hypomethylating agents Lower-Risk MDS paradigm: Focus on symptom thresholds to provide ongoing palliative support Lower-Risk MDS includes the very low- and low-risk categories of MDS with less severe, mildly active, or asymptomatic disease, slow evolution, a relatively indolent disease course, a low-to-absent need for therapy, and prolonged OS [56, 63]. However, in such a setting, the patient’s symptom burden may be significant and is often underestimated, as well as the risk of AML transformation [4, 62, 69–71]. For this group of patients, PC is not associated with a decline in health status but rather with the symptomatology of their chronic cytopenias [6, 68, 72–74]. In this context, the mainstay of clinical management is to support the patient’s functional status, prevent complications of bone marrow failure, preserve QoL, and prevent and treat cytopenias and transfusion dependence for red blood cells (RBCs) and/or platelets [5, 74]. In this context of supportive care for lower-risk MDS, erythropoietic-stimulating agents (ESAs) or luspatercept can be used to relieve anemia-related symptoms [74]. Indeed, these drugs have been shown to improve QoL, reduce the psychological impact of the condition, and minimize the need for RBC transfusions due to their significant physiological effects [14, 63]. If RBC transfusions are needed, the OS rate is reduced, and iron overload is a major concern that often requires chronic chelation therapy [1, 63]. Hypomethylating agents (HMAs) are well tolerated and effective in treating lower-risk MDS, including conditions such as transfusion-dependent anemia and thrombocytopenia. Their use is effective in cases where other treatments have failed. In this regard, the five-day azacitidine regimen has been found to confer the greatest survival benefit and may also reduce toxicity [47]. About PC, the NCCN guidelines show that the primary source for patients with lower-risk MDS should be the hematological team, which should address the patient’s distress and symptom burden [47]. Of note, the “watch and wait” approach, although proper from a clinical standpoint for asymptomatic lower-risk MDS, may translate into a “watch and worry” situation for some patients and their families. In this regard, PC timing should be addressed by providing psycho-educational support early on, normalizing their condition, and helping them cope with their disease status. This has been shown to have a positive impact on their psychological status, as shown by a study showing that when patients are provided with early psycho-educational support, they are not subjected to the anxiety and depression associated with being told they have a chronic malignancy [14–17]. Therefore, for patients with lower-risk MDS, a symptom-oriented strategy can be acceptable, providing treatments as symptoms become difficult to manage with standard methods [31]. In addition, the management of lower-risk MDS focuses on enhancing QoL through symptom management, such as treating chronic cytopenias, above all anemia and fatigue, alongside, not in place of, active disease treatments [71, 74]. In this regard, an early PC referral is recommended to control symptoms of chronic cytopenias and improve comfort, as these patients often need ongoing supportive care for years [40]. Therefore, patients with lower-risk MDS are primarily treated by hematology staff using simple palliative techniques, such as symptom management and communication [44, 47]. The intermediate-risk challenge: navigating prognostic uncertainty The intermediate risk group is defined as having an IPSS-R score of 3.0–4.5.0.5 points (Table 3). This is the ‘inflection point’ in the management of patients with MDS, as this group is where clinical outcomes vary greatly. Therefore, the management of Intermediate-Risk-MDS is influenced by whether the patient is more likely to fall on the lower or higher end of the intermediate spectrum [12]. In this regard, patients with a score < 3.5 (intermediate-1) or > 3.5 (intermediate-2) are managed as lower- or higher-risk groups, respectively. This group is in a clinical dilemma as the median OS is 3 years. In this regard, a retrospective study identified negative prognostic factors in this setting, including age > 66 years and RBC transfusions [64]. This group needs an aggressive therapeutic strategy due to rapid disease progression and the high risk of developing AML, with implications for the PC referral. Higher-risk MDS: the imperative for early specialist palliative care referral Patients with higher-risk MDS have a poor OS and an elevated risk of progressing to AML with clinical manifestations of a life-threatening condition that requires interventions to slow the progression of the disease, relieve symptoms, and prevent complications [65]. In this clinical setting, as in AML, the main goals of management are OS and, in selected patients, induction of remission with intensive chemotherapy or HMAs as well as combination therapies with tailored agents, ideally to bridge to allogeneic hematopoietic cell transplantation (HCT), which remains the only potentially curative option [1–3, 32, 66]. Patients in this group face a poor prognosis with a median OS of under 18 months, for which they demand specialized PC with early referral [22, 30, 34]. Therefore, for these patients, the early PC consultation should occur at the time of diagnosis or within the first 8 weeks of therapy initiation (Table 3), as for patients with AML [30]. In this regard, PC is not an alternative to disease-modifying therapy but rather a parallel support system to manage the disease-related symptom burden and the toxicity associated with therapies. Moreover, the prompt integration of early PC led to discussions regarding EOL care preferences, which is critical given the rapid decline of these patients, particularly in the setting of HMA failure, which represents a cataclysmic hematological outcome and a PC emergency. Indeed, failure of HMA is a clear and certain trigger for a change of gears to PC and EOL care. In the absence of any standard-of-care options following HMA failure, survival outcomes are extremely poor with a median OS of 4.6 months [66]. At this point, the role of the PC team is critical in managing the psychological trauma of disease and therapy failure for the patient and their family members. Therefore, the focus of care should now change from “fighting” the disease to maximizing the time spent with loved ones and managing severe and refractory cytopenias. In this regard, specialty PC teams are well-equipped to manage the “palliative emergency” of rapid disease progression and to ensure relief of pain and psychological symptoms for the patients as they transition into the EOL phase of disease [22]. The role of palliative care in the HCT trajectory Although HCT is the only curative treatment for many hematological malignancies, it is associated with considerable morbidity and mortality, especially in the older patient population, who dominate the incidence rate for MDS. In the past, the “curative intent” of HCT was perceived as an obstacle to the use of PC, as it was believed to undermine the patient’s hope. However, current guidelines for the care of patients with MDS encourage early PC involvement throughout the HCT course [75]. PC professionals can be particularly helpful during the pre-HCT evaluation period, helping the patient understand the trade-offs between curative potential and the risks of the HCT. In the transplant hospital, the main role of PC is the control of severe physical symptoms, including mucositis, nausea, and pain related to graft versus host disease. Additionally, for patients who are not suitable candidates for transplant due to high HCT-comorbidity index scores or poor performance status, the prompt application of PC is essential to help their transition to a non-curative approach [75]. Despite the curative nature of the procedure and its high risk of complications and mortality, HCT raises a critical question concerning the necessity of discussions about potentially fatal issues involving patients’ and caregivers’ perspectives and opinions now, content, and difficulties of having such conversations. In this context, it should be said that patients and caregivers feel a need to discuss issues related to dying from the time of diagnosis. However, discrepancies arose as the transplant procedure progressed [76]. A multicentre study conducted in Germany examined the complex triadic relationship in the HCT setting, involving 61 patients, 31 informal caregivers, and 125 healthcare professionals. The study offered a solid basis for understanding the communication gap between them. Indeed, while 61.7% of patients preferred that their caregivers go with them throughout the consultation process, caregivers often perceived the conversations as neglectful, with only 50% finding their conversations with healthcare professionals meaningful and useful [76]. In other words, healthcare professionals’ reluctance to discuss death was connected to their lack of awareness concerning the need to have this type of conversation with critically ill patients. There was a difference between patients and their families about when to discuss serious concerns, and a discrepancy between providers and patients about the discussion of serious health issues [76]. Palliative significance of refractory cytopenias Supportive treatment for many people suffering from MDS is done for reasons like age, presence of other illnesses, or time limitations. On the contrary, some people are left untreated as they don’t show any symptoms, and there is little chance of progression in the condition. Yet, throughout the course of the disease, anemia is the most encountered problem, affecting up to 90% of patients and being a major contributor to fatigue [56, 63, 67]. In this regard, patients with MDS may require ESA treatment, as well as novel agents or continuous transfusions of RBCs or platelets to manage anemia and thrombocytopenia, respectively, and to improve their QoL [77]. In this regard, an ideal transfusion regimen requires the right thresholds for hemoglobin and platelet counts [6, 56]. Although a restrictive regimen is often practiced, it is still unclear whether such a therapy would be suitable for outpatient MDS patients since they tend to be older, frail, and have several heart diseases [78, 79]. Moreover, there is insufficient evidence to demonstrate that liberal blood transfusion therapy improves short-term QoL in MDS without affecting OS [79]. Regarding the traditional non-transfusional treatment of anemia, a real-world EUMDS Registry with 2,448 patients, of whom 1,265 were unexposed to ESA, and 1,183 were treated with ESA, found that ESA treatment in lower-risk MDS patients significantly improves OS when started before or soon after regular transfusions. Moreover, avoiding RBC transfusions was associated with a notable boost in QoL [80, 81]. However, while raising hemoglobin levels is recommended, especially in critical clinical situations, other studies claimed that it does not guarantee improved QoL [82, 83]. Indeed, QoL is impaired in MDS, but the role of hemoglobin levels is unclear, and a nonlinear relationship between poor QoL and MDS-associated anemia suggests that QoL may be impaired by other factors, such as age, inflammatory diseases, and several medical comorbidities [79, 84–86]. Therefore, QoL in patients with anemic MDS may differ from that in non-MDS patients. Other anemia-related symptoms that patients with MDS may experience include dyspnoea, pallor, chest tightness, and chills [31, 56, 70]. Few studies have investigated how clinical management with non-curative therapies influences OS and leukemia-free survival (LFS) in patients with MDS. In this regard, a recently published study of the Düsseldorf MDS Registry found that patients receiving only RBC transfusions had different outcomes than those receiving RBC transfusions alongside other non-curative measures, such as iron chelation, ESAs, lenalidomide, and antithymoglobulin. In particular, the first three measures resulted in better OS and LFS than those seen in patients receiving RBC transfusions alone [60]. About other cytopenias, rather than anemia, thrombocytopenia and neutropenia each bring their own set of morbidities [68, 72, 73]. Reduced neutrophil counts make patients vulnerable to life-threatening infections, which often bring them to the emergency department and are the primary reason for extended hospitalization [68]. Additionally, low platelet counts lead to easy bruising and spontaneous bleeding, which can be both physically dangerous and psychologically distressing [6, 72, 73]. Particularly in the advanced stages of MDS, especially in the very high-risk groups, the bone marrow failure often leads to life-threatening complications, and patients are more likely to die from infections because of neutropenia and bleed to death because of thrombocytopenia [68, 72, 73]. The approach to PC management of complications prioritizes comfort over cure. For example, antibiotics are used to control infections, but relief of fever and uncomfortable respiratory symptoms is emphasized [68]. Similarly, platelet transfusions may be used to control life-threatening bleeding, such as gastrointestinal or intracranial hemorrhage, even when there is no chance of cure [72, 73]. Notably, end-stage bleeding also should be managed humanely, which includes the use of dark-coloured linen and prompt administration of sedatives if hemorrhage occurs during hospice treatment or at home in the phase of EOL care [72]. Managing the symptom spectrum: fatigue, dyspnoea, and pain The impact of MDS significantly disrupts the daily routines of patients and caregivers, going beyond the physical symptoms of cytopenia [5]. In fact, patients experience a disabling set of physical and psychological symptoms, which envelop their entire being [5, 31]. In this regard, the symptom burden of MDS patients is generally comparable to or even greater than that of patients with advanced solid tumors [35, 70]. The three most frequent symptoms in patients with newly diagnosed MDS were pain (55%), dyspnoea (63%), and fatigue (92%), with the latter contributing significantly to patients’ symptom burden [67]. Although pain is not directly associated with MDS and is not a primary symptom of the disease, it may be a symptom related to clinical complications, as well as treatment side effects, or associated with AML transformation. In addition, in some cases of MDS, patients may also experience joint and muscle pains due to an associated inflammatory autoimmune disease [86]. In some cases of MDS, patients may experience dyspnoea, with anemia as the primary cause, although other underlying factors may also contribute. Furthermore, patients with MDS may experience respiratory symptoms not linked to anemia [87]. Fatigue, affecting 90% of patients with MDS, is the most common symptom. It is notable because it does not improve with rest and serves as a key predictor of overall survival [67]. Fatigue results not only from reduced hemoglobin levels but also from a complex interplay of factors, including systemic inflammation, oxidative stress, and metabolic disturbances associated with MDS [5, 79, 86–88]. Fatigue management: beyond the hemoglobin threshold While ESAs and luspatercept, as well as RBC transfusions whenever necessary, are the primary treatment for fatigue related to anemia, they are often insufficient to manage the multidimensional fatigue of MDS. In this regard, PC clinicians use a combined approach of pharmacological and non-pharmacological interventions [79]. The former approaches to managing cancer-related fatigue are limited but may involve the use of corticosteroids in the terminal stages of MDS to improve energy levels and appetite. In addition, psychostimulants like methylphenidate and modafinil may be used [79]. Additionally, non-pharmacological interventions include energy conservation techniques in which patients prioritize tasks and schedule activities to align with their energy peaks [89]. Exercise, especially moderate aerobic activity, which may initially appear counterintuitive in the management of cancer-related fatigue, has the strongest evidence-based approach of all approaches [35]. Since disorders afflicting sleep are common secondary causes of fatigue in cancer patients, implementing sleep hygiene and cognitive behavioral therapy for insomnia are two effective strategies to enhance its quality [35, 36, 84]. The psychological burden and the prognostic uncertainty MDS can cause psychological distress, and it can be worse than the physical problems [20–22, 36]. Indeed, patients with MDS can suffer from emotional concerns that may include uncertainty about the future, frustration, as well as anxiety, depression, and apprehension about the progression of the disease, and the feeling of lost control of their lives [36]. About half of the people worry intensely about their future and their ability to plan for it, mainly because they have a poor understanding of their condition. The impact of the disease on their life is significant, with 38% suffering from moderate to severe anxiety or depression [37]. Some of the other factors that can add to the levels of anxiety and depression include the high symptom load, the incurable nature of the disease, limited therapeutic options, the transfusion dependency, the fear of developing AML, and the efficacy of treatment. The psychological effect of MDS on patients has an unpredictable “rollercoaster” course, with phases of relative stability followed by sudden clinical deterioration. This is referred to as “prognostic uncertainty” and is said to be “psychologically paralyzing” for the patient and families, who seek information from various sources on the internet to meet their needs [36]. In addition, ineffective communication with healthcare providers may contribute to their distress, especially when they feel they are not receiving enough information about their specific type of MDS [16–18, 35]. Notably, their caregivers may experience distress levels comparable to those of the patients themselves [14–16, 32]. Caregiver burden and the need for support Informal caregivers are the silent pillars of MDS care, often managing daily tasks and financial responsibilities as well as providing emotional support [16, 32, 33]. The emotional stress that the caregivers of MDS patients will face is inevitable, with more than 70% of them experiencing high degrees of anxiety and depression [16, 37]. The caregiving burden has been assessed using the Zarit Burden Interview [90]. The score among caregivers of patients with MDS was reported to be as high as 25.4, showing a moderate-to-severe burden. The time caregivers of MDS patients spend on caregiving activities is 45.4 h/week, which may be an underestimate [14]. Moreover, the QoL of the caregivers of MDS patients is expected to be lower than that of the general population, especially in the mental health/psychological functioning domain [14]. Caregiving interventions are informed by the PC clinical practice guidelines, which recommend that care be provided to the patient and caregiver together in a single unit (dyad), as this approach improves care management, reduces caregiver distress, and enhances communication [14–16, 37]. The use of caregiver support programs, including information exchange and emotional support, is beneficial for their resilience, reducing their stress and improving patients’ recovery and adaptation [14]. The multidisciplinary team in early PC for MDS MDS are intricate diseases characterized by variable and evolving clinical and symptomatic progression. Like other chronic illnesses with undulating and unpredictable courses that feature episodes of acute symptoms, sudden deterioration, and severe clinical complications, they need a multidisciplinary and integrated approach customized to meet the needs of patients and their caregivers. In this regard, a multidisciplinary team in PC brings together several care professionals to deliver holistic, coordinated care to patients with serious illnesses and their families [91]. This collaborative approach addresses physical, psychological, social, and spiritual needs to improve QoL, manage complex symptoms, and ensure effective communication and education, to provide the patient with sufficient information about his/her diagnosis to make an informed decision [16–18]. In addition, advance care planning enables patients to communicate their care preferences, ensuring that EOL treatments align with their values and wishes [22, 28, 29]. In this aim, the multidisciplinary team should include most of the following professionals: a hematologist, a PC specialist, a nurse navigator or leader, a social worker or psychologist, and a pharmacist. In such a multidisciplinary team, the hematologist manages patients with MDS, evaluates risks, and treats clinical complications. In contrast, the PC specialist manages symptoms, supports patient coping strategies, and addresses goals of care and advanced care planning [22, 28, 29]. In addition, the nurse navigator coordinates care and manages care flow for remote patient monitoring services, while the social worker-psychologist addresses psychosocial needs and financial concerns [33]. Again, pharmacists can help physicians design a pharmacological regimen and manage and prevent drug interactions [45, 92]. Reductions in aggressive end-of-life care by early PC in MDS Among EOL patients with MDS and other hematological malignancies, symptom burden is high, and QoL is diminished [51, 52, 93]. In this regard, early PC was associated with a higher likelihood of home or hospice death, allowing for the respect of patients’ wishes and choice and the peaceful death in one’s own community, as well as substantial cost savings [51, 52]. Indeed, early PC was associated with lower healthcare use, including fewer transfusions, reduced chemotherapy, aggressive clinical measures, hospitalizations, and intensive care admissions near the EOL [51, 52, 94]. In the hospital setting, early completion of portable medical orders before admission was associated with lower-intensity care and reduced inpatient costs during the EOL phase among AML and MDS patients [95]. Table 5 provides indicators of the quality of EOL care for dying patients, as reviewed in papers addressing these issues in hematological malignancies [30, 51, 52]. Table 5Indicators of quality of EOL care [22, 26, 30, 54, 55]EOL care indicator.Comment.Pain.Effective management of pain, dyspnea, and other distressing symptoms is critically important in this context.Physical Comfort.Creating a comfortable environment by ensuring proper positioning, keeping cleanliness, and controlling temperature.Physical Changes.Monitor for physical signs such as reduced urine output, cold limbs, and variations in heart rate or blood pressure.Emotional and Psychological Indicators.Recognize and address feelings of anxiety, depression, and other emotional concerns.Spiritual Needs.Acknowledge and respect the patient’s spiritual or existential worries.SDMAllow the patient and family to make decisions on care.QoLEnsuring that the maintenance or improvement of the person’s QoL is prioritized to the greatest extent possible.ACPEnsuring that the ACPs are completed and shared with the concerned people.Communication.Facilitating correct and prompt communication between the healthcare team, the individual, and the individual’s family.Coordination of Care.Measurement of coordination of care across different healthcare sites and providers.Location of Death.Considering the patient’s preference for their place of passing (e.g., at home, in hospice, in the hospital).Aggressive vs. PC.Comparison of aggressive interventions (such as frequent hospitalizations and ICU stays) with more palliative options (like hospice and home care).PC Access.Evaluation of the use and availability of PC services, including pain management, symptom relief, and psychosocial support.Hospitalizations and ED Visits.Monitoring hospitalizations and ED visits during the terminal stage of illness.ICU Admissions.Evaluating the use of the ICU during the EOL stage.Physician House Calls.A righter measure of a patient-centered care initiative is calculating the number of physician house calls.Home PCEvaluating PC delivered to the Home.Indicators for the quality of EOL care in acute hospitals.These indicators focus on specific areas of care delivery in acute hospital settings, including pain management and communication.EOL end-of-life; Shared Decision-Making; QoL quality of life, ACP advanced care planning, PC palliative care, ED emergency department, ICU intensive care unit Indicators of quality of EOL care [22, 26, 30, 54, 55] EOL end-of-life; Shared Decision-Making; QoL quality of life, ACP advanced care planning, PC palliative care, ED emergency department, ICU intensive care unit Barriers to timely PC in MDS Despite updated recommendations for PC, barriers to its early integration in hematology remain. The biggest barrier to the integration of PC and hospice among MDS patients is transfusion dependence. For MDS, the transfusions tend to be classified as “supportive/palliative,” as they are used to relieve symptoms such as dyspnea or fatigue. The patients who rely on the transfusions tend to have a higher chance of entering the hospice, primarily because their condition is considered more serious. Nonetheless, the duration of stay at the hospice is much shorter in such cases than in patients receiving transfusions [52, 53, 96, 97]. This transfusion paradox means patients should choose between the PC offered in the hospice setting and the supportive effects of RBC transfusions, thus staying in the hospital until they die, preventing the patient from a peaceful demise at home, and subjecting them to aggressive care at the EOL [97]. In addition, major barriers to the early implementation of PC in MDS patients are the cultural beliefs in the field of hematology that PC means giving up on the hope for curing the disease. Furthermore, concerns include provider- and patient-related issues, as well as systemic challenges [32, 49, 50, 84, 96, 97]. Moreover, the unstable course of MDS, with periods of cytopenia normalization and transformation into AML, does not help define the stage for palliation [32]. In contrast, solid cancers require non-curative treatment once metastatic disease develops [35]. Therefore, patients suffering from MDS can receive further help using new drugs to go into remission despite relapses, prompting the clinician to delay until death the patient’s referral for PC, thereby missing the opportunity to integrate it at an earlier stage [30, 53, 98]. Of note, hematologists form an emotional bond with their patients that has been shown to influence resistance to EOL discussions [22, 50]. Moreover, physicians’ beliefs that they have failed to provide care to patients, or that doing so will destroy patients’ hope, also make them reluctant to discuss EOL care. Notably, a recent survey found that 73% of hematologists are not familiar with effective goal-of-care conversations [53]. Therefore, unrealistic expectations for novel therapies may also lead both clinicians and patients to support a curative focus at the wrong time [32, 49, 53, 97]. The use of PC is also associated with misconceptions among patients, as reflected in an 82% concern rate among patients with MDS about the term [17]. These wrong convictions arise from cultural and religious beliefs that view any discussion about death as taboo and, more specifically, the patients’ lack of trust in caregivers and care systems [17, 49, 50]. To address clinician-related problems such as delayed diagnosis, excessive clinician optimism, or personal disappointment, institutions should consider systematic screening and trigger mechanisms to ensure prompt PC referral. The process of developing a PC prompt requires a systematic institutional procedure and access to resources, such as staffed outpatient specialist PC clinics [33]. Such actions would help present PC as a proactive intervention rather than as an approach for hopeless cases [33]. Good doctor-patient relationships, typical among hematologists, may be one reason for the “failure of recognition” at the terminal stage of disease. In some cases, clinicians do not want to refer patients to PC services because they fear that PC involvement could mean less hope for patients or a sense of defeat [46, 98]. However, it has been shown that although almost all healthcare professionals (99%) are convinced of the importance of PC and its need in education, most of them (77%) are not ready to provide it [98]. This discrepancy creates a divide between recognizing the importance of specialized PC and practitioners’ ability to provide it in practice, often resulting in lower confidence in managing EOL [9]. On the other hand, patients tend to associate PC and hospice with imminent death, which causes their discomfort and unwillingness to get involved in the program [22, 28, 62]. Some measures, such as educational interventions using informational videos and pamphlets that explain PC’s purpose as a supportive treatment, should be implemented [52, 91]. Table 6 shows the most common barriers to PC and potential strategies to overcome them in MDS and hematological malignancies [32, 52, 53]. Table 6Main barriers to PC and possible strategies to address them in MDS and hematological disorders malignancies [30, 52, 53, 95, 97]BarriersCommentsOvercoming strategiesACPACP has been demonstrated to decrease invasive care at EOL.ACP enables patients to openly and honestly express their EOL care needs and treatment goals, empowering them to make informed decisions with confidence and peace of mind.Comprehension and communicationPatients with MDS often have difficulty articulating their experiences to hematologists and may find it challenging to share their symptoms, concerns, and treatment objectives openly.PC professionals can create a welcoming environment where patients and their caregivers feel at ease sharing their needs and concerns. This promotes clear communication with hematologists regarding prognosis, care plans, and the benefits of PC.CostLimited funding and workforce shortages may restrict access to hospice, high-quality EOL care, PC, and transfusions.Changes to the reimbursement policy could increase enrollment in hospice programs.Cultural SensitivitySpecific cultural settings should be considered.Offering personalized care that respects and honors each person’s unique cultural background.Misunderstandings and acceptabilityThere is widespread misinformation about PC, as both patients and healthcare providers often think it is only for EOL situations or equate it with giving up. This misconception discourages patients from seeking vital emotional support and from managing their symptoms.Educational and public awareness campaigns are essential in fighting misinformation and emphasizing the benefits of PC, such as improvements in QoL, symptom management, and addressing psychosocial challenges.Multidisciplinary Approach.Poor coordination between hematologists and PC specialists can pose challenges in providing integrated care to patients.Effective care requires close collaboration among hematologists, primary care specialists, social workers, nurses, and other healthcare providers.Personalized HealthcareBecause MDS requires tailored treatment plans and strategies, PC should be customized to address each person’s specific needs.When evaluating PC, the balance between the likelihood of cure and the effects of intensive therapies on QoL should be considered.Physician TrainingHematologists typically lack a background in PC and symptom management.Hematologists should get basic training in PC.ReferralsLate referrals often limit palliative care to EOL care.Early PC enables medical professionals to carefully evaluate patients’ needs and manage AML treatment while supporting patients’ overall well-being.Staffing and availabilityCare professionals encounter challenges and opportunities due to limited knowledge of PC and its importance.PC training for hematology professionals, including integrating PC professionals into the medical treatment team and holding periodic consultations with them.TransfusionsTransfusion support is frequently unavailable in hospice care, which significantly limits patients with blood cancer from enrolling. Key reasons include cost, concerns about EOL transfusions, hospital policies, and physicians’ opinions.Further research is needed to assess the effectiveness of transfusions in EOL treatment. Moreover, additional reimbursement should be allocated for PC and hospice-related transfusions.PC palliative care, AML acute myeloid leukemia, EOL end-of-life, QoL quality of life, ACP advanced care planning Main barriers to PC and possible strategies to address them in MDS and hematological disorders malignancies [30, 52, 53, 95, 97] PC palliative care, AML acute myeloid leukemia, EOL end-of-life, QoL quality of life, ACP advanced care planning Integration of comprehensive EPC models in MDS: clinical framework and actionable recommendations for hematologists Advancements in early PC for MDS management are needed to continue providing comprehensive and compassionate patient care. In this regard, future advancements will involve integrating precision medicine and technology into digital health and creating tailored care plans for patients with MDS from disease onset, including the proper timing of referral to a PC program [99, 100]. Using digital platforms to collect and analyze patient-reported outcomes (e-PROs) enables real-time monitoring of patients’ MDS symptoms, improves communication between patients and clinicians, and provides a deeper understanding of changes in QoL during treatment [100]. These platforms can automatically alert the PC specialist or oncologist if patients’ symptoms become uncontrolled, helping prevent escalation before hospitalization becomes necessary [100]. Moreover, the development of new patient-centered therapeutic solutions, such as oral causal therapies, may also change the clinical landscape and the evolving management of MDS and hematological malignancies, including the right application of PC programs [58, 91]. In addition, advocates for policy change to cut barriers to integrating hospice and transfusion services by passing proper legislation and aligning payment policies among policymakers and providers. Again, incorporating PC rotations and communication training into hematology fellowship programs is an essential approach to addressing physician reluctance and forming medical professionals equipped to have open, empathic, and compassionate conversations early in the disease course to discuss prognosis and treatment goals with patients with MDS [98]. Table 7 presents actionable recommendations derived from the present review for hematologists caring for patients with MDS. Table 7Early PC in MDS: actionable recommendations for hematologistsDomainActionable recommendationTiming/MilestoneReferralRefer patients with High/Very High risk to outpatient PC.At diagnosis or risk re-stratification.ScreeningImplement routine screening in the outpatient clinic.Every 1–3 months, or at symptom/treatment changes.EOL PlanningDiscuss the logistical barriers to hospice transfusions and find a “preferred place of death”.When the prognosis is estimated at < 3 months.Team CareInvolve a social worker for functional/financial assessment and a chaplain for spiritual support.Early in the disease course for all high-risk patients.MonitoringTrack performance status and fatigue as independent prognostic factors.At every clinic encounter.FatigueUse symptom-based transfusion triggers; ESAs/Luspatercept use to reduce TD.Throughout the disease course.DyspneaInitiate low-dose immediate-release morphine for refractory “air hunger”.When symptoms are no longer responsive to transfusions.CommunicationConduct and document a Serious Illness Conversation.At diagnosis (always) and more intensively at HMA failure or AML evolution.Hospice Cost ModelsDisallows palliative transfusions, leading to late referral.Find “transfusion-friendly” hospices or concurrent care options.Disease UncertaintySudden transformation to AML complicates the timing of EOL.Preparing and promoting a prompt for GOC discussions.Aggressive EOL CareHigh rates of ICU and chemo within 14 days of death.Implement the Serious Illness Conversation Guide at HMA failure.Caregiver BurdenHigh logistical demand for transfusion-dependent patients.Early referral to PC social worker for home support and respite.PC palliative care, MDS myelodysplastic syndromes, ESAs erythropoietic stimulating agents, TD transfusion-dependence, HMA hypomethylating agents, AML acute myeloid leukemia, EOL end of life, GOC goals of care conversations, ICU intensive care unit Early PC in MDS: actionable recommendations for hematologists PC palliative care, MDS myelodysplastic syndromes, ESAs erythropoietic stimulating agents, TD transfusion-dependence, HMA hypomethylating agents, AML acute myeloid leukemia, EOL end of life, GOC goals of care conversations, ICU intensive care unit Conclusions Managing MDS needs a comprehensive approach, as the disease cannot be treated without considering its unique features. In this regard, the early and efficient application of primary PC in virtually all cases, and the introduction of specialist PC into the treatment of patients with advanced MDS or higher-risk cases, can hopefully be viewed as important goals. In addition, the collaboration with PC specialists will help maximize patients’ QoL, reduce the psychological impact on patients, and avoid invasive therapy during the final period of their lives. Therefore, the role of early PC in MDS requires a paradigm shift from a supportive EOL service to an integral part of the comprehensive management as needed. Indeed, the high symptom burden, combined with the prognostic uncertainty inherent to MDS, requires an initiative-driven approach right from the time of diagnosis. Based practice is necessary to enhance physical and functional symptoms, alleviate psychological morbidity, and reduce resource use by avoiding inappropriate EOL care. Despite current challenges in EOL care, including physicians’ misperceptions of survival probabilities, public misconceptions, and the difficulty of implementing EOL care, ongoing digital and cultural changes are bringing positive developments to the field [36, 53]. The integration of PC in the management of MDS is not only a clinical and ethical responsibility of the specialists but also an opportunity to manage medical resources effectively [33]. In conclusion, early PC in MDS is expected to become a key arena for precision medicine and digital innovation in the near future [99, 100]. The incorporation of early PC into the management of MDS and other blood cancers can enable new approaches by hematologists, shifting the focus from traditional clinical management to an emphasis on patients’ values and QoL. Acknowledgements No disclaimer. No funds have been received for this manuscript.The authors have no conflict of interest. Author contributions P.N., V.G., M.G., C.M., and M.I.D.P. searched for and critically reviewed the articles included in the present review.P.N. drafted the paper.P.N., V.G., M.G., C.M., and M.I.D.P. critically reviewed the paper and approved the content of its final version.M.I.D.P. approved submission of the final version of the paper.No disclaimer. No funds have been received for this manuscript.The authors have no conflict of interest. Funding No funds have been received for this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.